Stanford Cardiovascular Institute
Regenerative & Precision Cardiology—From Patient Stem Cells to Clinical Trials
About the Organization
The Stanford Cardiovascular Institute (CVI) brings together world-leading scientists, clinicians, and engineers to transform how we prevent, diagnose, and treat cardiovascular disease. Teams leverage patient-derived stem cells (iPSCs), organoids, advanced imaging, and genomics to model disease, discover drug targets, and move promising ideas into clinical trials. Through seed grants, training programs, and translational cores—including the flagship SCVI iPSC Biobank with 1,700+ patient lines—CVI accelerates breakthroughs from bench to bedside.
Key Facts
Why I Support This Cause
Cardiovascular disease affects every family. The Stanford Cardiovascular Institute is pioneering regenerative and precision cardiology—from patient-specific stem cells and organoids to clinical trials. Backing CVI means investing in science that can turn today's insights into tomorrow's therapies.
"We're building clinical trials in a dish to make therapies safer, faster, and more personalized."
— Joseph C. Wu, MD, PhD, Director, Stanford Cardiovascular Institute